Skip to main navigation
Go to Cumberland Pharmaceuticals, Inc. homepage
  • About Us
    • Profile & Mission
    • Our Strategy
    • Board of Directors
    • Management Team
    • Company History
  • Our Products
    • Commercial Products
    • Pipeline Products
    • International Partners
  • Investor Relations
    • Overview
    • Corporate Update
    • Corporate Governance
      • Committee Composition
      • Contact the Board
    • Stock Information
      • Historic Price Lookup
      • Ownership Profile
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
      • Key Ratios
    • Earnings Calls & Presentations
    • Investor FAQs
    • Press Releases
    • Contact Investor Relations
  • News
  • Cumberland Emerging Technologies
  • Blog
  • About Us
    • Profile & Mission
    • Our Strategy
    • Board of Directors
    • Management Team
    • Company History
  • Our Products
    • Commercial Products
    • Pipeline Products
    • International Partners
  • Investor Relations
    • Overview
    • Corporate Update
    • Corporate Governance
      • Committee Composition
      • Contact the Board
    • Stock Information
      • Historic Price Lookup
      • Ownership Profile
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
      • Key Ratios
    • Earnings Calls & Presentations
    • Investor FAQs
    • Press Releases
    • Contact Investor Relations
  • News
  • Cumberland Emerging Technologies
  • Blog
Contact
Contact

Key Ratios

Valuation

P/E (TTM)
P/E (FY)
P/E 5 Fiscal Year High
P/E 5 Fiscal Year Low
Price to Revenue (TTM) 0.97
Price to Revenue (MRQ) 0.79
Price to Revenue (FY) 0.97
Price to Cash Flow (TTM) 33.30
Price to Cash Flow (MRQ)
Price to Cash Flow (FY) 33.30
Price to Free Cash Flow (TTM) 9.07
Price to Free Cash Flow (FY) 9.07
Price to Book (MRQ) 1.73
Price to Book (FY) 1.73
Price to Tangible Book (MRQ) 4.33
Price to Tangible Book (FY) 4.33
Price to Tangible Book - Common (MRQ) 5.99
Price to Tangible Book - Common (FY) 5.99

Profitability

Operating Margin (TTM) (%) -6.27
Operating Margin (MRQ) (%) -10.02
Operating Margin (FY) (%) -6.27
Net Profit Margin (TTM) (%) -6.40
Net Profit Margin (MRQ) (%) -10.35
Net Profit Margin (FY) (%) -6.40
Gross Margin (TTM) (%) 85.02
Gross Margin (MRQ) (%) 83.61
Gross Margin (FY) (%) 85.02

Per Share

Revenue/Share (TTM) $2.98
Revenue/Share (MRQ) $3.77
Revenue/Share (FY) $3.00
EPS Fully Diluted (TTM) $-0.19
EPS Fully Diluted (MRQ) $-0.10
Book Value/Share (MRQ) $1.66
Book Value/Share (FY) $1.66
Cash Flow/Share (TTM) $0.09
Cash Flow/Share (MRQ) $-0.10
Cash Flow/Share (FY) $0.09
Cash (MRQ) $0.77
Cash (FY) $0.77

Growth

5 Year Annual Growth (%) 3.95
5 Year Annual Dividend Growth Rate (%)
5 Year Annual Revenue Growth Rate (%) 3.52
5 Year EPS Growth

Financial Strength

Quick Ratio (MRQ) 0.84
Quick Ratio (FY)) 0.84
Current Ratio (MRQ) 1.01
Current Ratio (FY) 1.01
LT Debt to Equity (MRQ) (%) 21.06
LT Debt to Equity (FY) (%) 21.06
Total Debt to Equity (MRQ) (%) 21.06
Total Debt to Equity (FY) (%) 21.06

Efficiency

Receivables Turnover (TTM) 3.11
Receivables Turnover (MRQ) 4.01
Receivables Turnover (FY) 3.11
Asset Turnover (TTM) 0.58
Asset Turnover (MRQ) 0.77
Asset Turnover (FY) 0.58
Inventory Turnover (TTM) 1.30
Inventory Turnover (MRQ) 1.96
Inventory Turnover (FY) 1.30

Management Effectiveness

Return on Equity (TTM) (%) -11.88
Return on Equity (MRQ) (%) -22.20
Return on Equity (FY) (%) -11.88
Return on Assets (TTM) (%) -3.74
Return on Assets (MRQ) (%) -7.96
Return on Assets (FY) (%) -3.74
Return on Investment (TTM) (%) -6.73
Return on Investment (MRQ) (%) -13.79
Return on Investment (FY) (%) -6.73

FY = Fiscal Year. MRQ = Most Recent Quarter. mil = Millions. TTM = Trailing Twelve Months.

Source: LSEG

© 2026 Cumberland Pharmaceuticals, Inc. All Rights Reserved.

Privacy Policy
Accessibility Statement
Terms of Use